A
Description
Biotech company based in Stevenage, UK, founded in 2013 by David Sharples and Nicholas Larkins. Identifies and synthesizes plant-origin secondary metabolites. Lead clinical asset is APPA, a patented drug in clinical development for osteoarthritis (pain, functionality, cartilage). Also developing TAKL for asthma and COPD. Partner with University of Liverpool.